ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Portfolio Management Lead at Revolution Medicines - ApplyBlast

Portfolio Management Lead

Revolution Medicines

1 month ago

3.5 on Glassdoor

Redwood City, California, United States

Onsite

Full Time

Senior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The role partners with PDM leadership and cross‑functional stakeholders to support portfolio planning, business operations, and strategic decision‑making. It leads analyses, reporting, and governance activities, driving data‑driven insights, resource allocation, and execution of business objectives across the organization.

Responsibilities

Partner with PDM leadership and cross-functional stakeholders to support portfolio planning and strategic decision‑making
Lead development analyses, insights, and recommendations to enable prioritization and resource allocation
Drive cross‑functional planning and governance activities by facilitating stakeholder alignment

Skills

Qualifications

B.Sc. in a scientific, engineering, business, or related disciplineAdvanced degree in a scientific, engineering, business, or related disciplinePMP or similar project management certification

About Revolution Medicines

revmed.com

Headquarters

Redwood City, California, United States

Company Size

201-500 employees

Founded

2014

View Profile

Revolution Medicines (RevMed) is a biopharmaceutical company dedicated to discovering, developing, and delivering novel targeted medicines for patients with cancer. Their mission focuses specifically on "revolutionizing treatment for patients with RAS‑addicted cancers" through precision-targeted therapies. The company emphasizes a science-driven, end-to-end approach from discovery to delivery. RevMed brands its team as "Revolutionaries" committed to transforming outcomes for people with RAS‑driven tumors.